Dear Colleagues,

This Special Issue focuses on translational science in the hopes of shedding light on overcoming novel tumour therapy resistance. In fact, acquired drug resistance is one of the main restrictions to the efficacious treatment of cancer. There are many data showing that resistance results from drug exclusion, drug metabolism, and modification of the drug target by mutation or overexpression. Depending on the therapy, one or more genetic or epigenetic modulations are required to confer resistance to treatment.

The editor already works in a translational team from bench to bedside. She welcome submissions from researchers involved in basic cancer research but also in clinical activities. She has a deep knowledge of cancer therapy and target therapy such as tyrosine kinase and cyclin-kinases inhibitor, examined with the most different methods, biochemistry, immunohistochemistry, immunofluorescence, RT-qPCR, NGS, etc. It is required to have a clear understanding of tumour cells, and to clarify the ways that lead to therapy resistance from cell lines to clinical trials. Reviews and original papers are both welcome.

Dr. Nicoletta Cordani
Dr. Emanuela Grassilli 
Dr. Geeta Sharma
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer therapy resistance
• target therapy
• liquid biopsy
• circulating cancer DNA
• exosomes in cancer